Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 3/2013

01-09-2013 | Original Article

Detection and Characterization of Parathyroid Adenoma/Hyperplasia for Preoperative Localization: Comparison Between 11C-Methionine PET/CT and 99mTc-Sestamibi Scintigraphy

Authors: In Kook Chun, Gi Jeong Cheon, Jin Chul Paeng, Keon Wook Kang, June-Key Chung, Dong Soo Lee

Published in: Nuclear Medicine and Molecular Imaging | Issue 3/2013

Login to get access

Abstract

Purpose

11C-Methionine PET/CT (Met-PET/CT) is a useful imaging method for detection of parathyroid adenoma; however, the reported detection rate has been variable. The current study was intended to investigate detection sensitivity and preoperative localization of parathyroid adenoma (PA) or parathyroid hyperplasia (PH) on Met-PET/CT compared with 99mTc-sestamibi (MIBI) scintigraphy in patients with primary hyperparathyroidism (HPT) or suspected PA.

Methods

Met-PET/CT and MIBI scintigraphy images were reviewed by two nuclear medicine physicians unaware of pathologic results. Detection sensitivities and preoperative localization of detected parathyroid tissues into five predefined segments were evaluated by visual assessment and semi-quantitative analysis with ratio of standardized uptake values (SUVR) between parathyroid tissue and normal lung as reference. Linear regression analysis with SUVR and serum parathyroid hormone (sPTH) was performed for characterization of PA or PH. Predicted PTH (pPTH) was calculated and compared with sPTH in PH and PA. Each pPTH was obtained for a calculated SUVR by using linear regression model from the result of previous linear regression analysis between SUVR and sPTH.

Results

In 16 patients, detection sensitivities of Met-PET/CT and MIBI scintigraphy were 91.7 % (11/12) and 41.7 % (5/12) for PA and PH including both biopsy-confirmed and clinically-suspected cases, and 100 % (8/8) and 50 % (4/8) for pathologically confirmed PA and PH cases only, respectively. Met-PET/CT showed higher performance than MIBI scintigraphy in localization of parathyroid tissues; correct localization rate was 87.5 % (7/8) on Met-PET/CT and 50 % (4/8) on MIBI scintigraphy. In semi-quantitative analysis, SUVR was linearly associated with sPTH by linear regression analysis (sPTH = 39.53 × SUVR − 89.84, p = 0.0383). There was a borderline significant difference in pPTH between PH and PA (35.1 vs 204.7 ± 164.0, p = 0.052), while there was no significant difference in sPTH between PH and PA (289 vs 230.4 ± 160.4, p = 0.305).

Conclusions

Met-PET/CT has a potential to be a useful diagnostic modality for preoperative detection and localization of parathyroid tissues with higher sensitivity than MIBI scintigraphy, and for characterization of PA or PH.
Literature
1.
Taillefer R. Tc-99m sestamibi parathyroid scintigraphy. In: Freeman LM, editor. Nuclear Medicine Annual 1995. New York: Raven Press; 1995. p. 51–79.
2.
Vestergaard P, Thomsen SS. Medical treatment of primary, secondary, and tertiary hyperparathyroidism. Current Drug Safety. 2011;6:108–13.PubMedCrossRef
3.
Hindie E, Ugur O, Fuster D, O’Doherty M, Grassetto G, et al. EANM parathyroid guidelines. Eur Nucl Med Mol Imaging. 2009;36:1201–16.CrossRef
4.
Weber T, Cammerer G, Schick C, Solbach C, Hillenbrand A, et al. C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism. Horm Metab Res. 2010;42:209–14.PubMedCrossRef
5.
6.
Cheon M, Choi JY, Chung J, Lee JY, Cho SK, et al. Differential findings of Tc-99m sestamibi dual-phase parathyroid scintigraphy between benign and malignant parathyroid lesions in patients with primary hyperparathyroidism. Nucl Med Mol Imaing. 2011;45:276–84.CrossRef
7.
Grant CS, Thompson G, Farley D, Heerden J. Primary hyperparathyroidism surgical management since the introduction of minimally invasive parathyroidectomy. Arch Surg. 2005;140:472–9.PubMedCrossRef
8.
Hiromatsu Y, Ishibashi M, Hishida H, Okuda S, Miyake I. Technetium-99m tetrofosmin parathyroid imaging in patients with primary hyperparathyroidism. Internal Medicine. 2000;39(2):101–6.PubMedCrossRef
9.
Eslamy HK, Ziessman HA. Parathyroid scintigraphy in patients with primary hyperparathyroidism: 99mTc Sestamibi SPECT and SPECT/CT. Radiographics. 2008;28:1461–76.PubMedCrossRef
10.
Phillips CD, Shatzkes DR. Imaging of the parathyroid glands, semin in ultrasound. CT and MRI. 2012;33:123–9.CrossRef
11.
Zhu A, Shim H. Current molecular imaging positron emitting radiotracers in oncology. Nucl Med Mol Imaging. 2011;45:1–14.CrossRef
12.
Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, et al. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med. 2012;37(2):158–63.PubMedCrossRef
13.
Shiiba M, Ishihara K, Kimura G, Kuwako T, Yoshihara H, et al. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. Ann Nucl Med. 2012;26(2):138–45.PubMedCrossRef
14.
Frelinger III AL, Zull JE. The role of the methionine residues in the structure and function of parathyroid hormone. Arch Biochem Biophys. 1986;244(2):641–9.PubMedCrossRef
15.
Potts JT, Murray TM, Peacock M, Niall HD, Tregear GW, et al. Parathyroid hormone: Sequence, synthesis, immunoassay studies. Am J Med. 1971;50:639–49.PubMedCrossRef
16.
Otto D, Boerner AR, Hofmann M, Brunkhorst T, Meyer GJ, et al. Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET. Eur J Nucl Med Mol Imaging. 2004;31:1405–12.PubMedCrossRef
17.
Beggs AD, Hain SF. Localization of parathyroid adenomas using 11C-methioninepositron emission tomography. Nucl Med Commun. 2005;26:133–6.PubMedCrossRef
18.
Tang BN, Moreno-Reyes R, Blocklet D, Corvilain B, Cappello M, et al. Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. Contrast Media Mol Imaging. 2008;3:157–63.PubMedCrossRef
19.
Herrmann K, Takei T, Kanegae K, Shiga T, Buck AK, et al. Clinical value and limitations of [(11)C]-Methionine PET for detection and localization of suspected parathyroid adenomas. Mol Imaging Biol. 2009;11:356–63.PubMedCrossRef
20.
Tublin ME, Pryma DA, Yim JH, Ogilvie JB, Mountz JM, Bencherif B, et al. Localization of PAs by sonography and technetium tc 99m sestamibi single-photon emission computed tomography before minimally invasive parathyroidectomy: Are both studies really needed? J Ultrasound Med. Feb 2009;28(2):183–90.
21.
Caldarella C, Treglia G, Isgro MA, Giordano A. Diagnostic performance of positron emission tomography using 11C-methionine in patients with suspected parathyroid adenoma: A meta-analysis. Endocrine. 2013;43(1):78–83.PubMedCrossRef
22.
Rubello D, Fanti S, Nanni C, Farsad M, Castellucci P, et al. 11C-methionine PET/CT in 99mTc-sestamibi-negative hyperparathyroidism in patients with renal failure on chronic haemodialysis. Eur J Nucl Med Mol Imaging. 2006;33:453–9.PubMedCrossRef
23.
Oksuz MO, Dittmann H, Wicke C, Mussig K, Bares R, et al. Accuracy of parathyroid imaging: A comparison of planar scintigraphy, SPECT, SPECT-CT, and C-11 methionine PET for the detection of parathyroid adenomas and glandular hyperplasia. Diagn Interv Radiol. 2011;17:297–307.PubMed
Metadata
Title
Detection and Characterization of Parathyroid Adenoma/Hyperplasia for Preoperative Localization: Comparison Between 11C-Methionine PET/CT and 99mTc-Sestamibi Scintigraphy
Authors
In Kook Chun
Gi Jeong Cheon
Jin Chul Paeng
Keon Wook Kang
June-Key Chung
Dong Soo Lee
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 3/2013
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-013-0212-x

Other articles of this Issue 3/2013

Nuclear Medicine and Molecular Imaging 3/2013 Go to the issue

Interesting Image

Biliary Flow in Septate Gallbladder on Hepatobiliary Scintigraphy with SPECT/CT

Interesting Image

Usefulness of 18F-FDG-PET/CT in Evaluating a Brainstem Glioma in an Adult Patient with Neurofibromatosis Type 1

Case Report

Unsuspected Active Sarcoidosis Diagnosed by 18F-FDG PET/CT During the Search for a Primary Tumour in a Patient with Bone Lesions

Original Article

Clinical Usefulness of Serum CYFRA 21–1 in Patients with Colorectal Cancer

Case Report

Myocardial Fibrosis in Hypertrophic Cardiomyopathy Demonstrated by Integrated Cardiac F-18 FDG PET/MR

Interesting Image

Pyelo-cystic Reflux in F-18 FDG PET Scan Due to Ureteral Obstruction